TriSalus Q3 revenue up 42% to $7.3M; guides for 50%+ growth and positive EBITDA in 2025

TriSalus Life Sciences, Inc.

2024-Q3 EPS reported -$0.91 revenue$21,170,000

Q3 revenue $7.3M (+42% YoY); nine-month revenue $21.2M (+66% YoY). Gross margin 86%.
Operating loss improved to $8.7M (Q3) and $28.6M (9M) from $18.6M and $40.2M in 2023.
Net loss per share $0.12 (Q3) vs $0.14; cash $11.3M plus $25M OrbiMed facility.
2025 guidance: >50% revenue growth, >20% opex reduction, positive full-year EBITDA, H2 cash flow positive.
Launched TriNav LV system and TriGuide catheter; initiated PROTECT trial for thyroid embolization ($400M market).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.